Amount of Baseline Ischemia in Patients with Multivessel Disease and Long-Term Progress

According to this recent analysis of the MASS II trial, which will soon be published in JAMA, baseline ischemia is not associated with events at 10 years in patients with chronic stable angina.

The ischemic burden induced through exercise does not predict events or long-term ventricular function. Such data add some suspense to the results of the ISCHEMIA study.

These results were consistent regardless the therapeutic strategy applied in the MASS II study.

The controversy between the documented amount of ischemia and long-term events in patients with chronic stable angina is the long-term objective of the ISCHEMIA trial, which aims to determine the best strategy between revascularization plus optimal medical treatment vs. optimal medical treatment alone in patients with moderate or severe ischemic burden in stress testing. We are still waiting for the 5-year follow-up results of ISCHEMIA, but this analysis gives us a hint of what may be its 10-year follow-up results.


Read also: How to Prevent Pharmacological Overtreating in the Elderly.


These 10-year results of MASS II are consistent with results from the COURAGE trial, the BARI 2D trial, and the CLARIFY registry.

The MASS II trial randomized 611 patients to optimal medical treatment alone vs. angioplasty or myocardial revascularization surgery plus optimal medical treatment (in both cases) in stable patients with multivessel disease. MASS II enrolled patients during the late 1990s; consequently, it should be noted that there have been significant changes in medical treatment and, mainly, angioplasty since that time.

After a decade of follow-up, there is no documented evidence indicating an association between the presence of baseline ischemia and survival free of cardiovascular events, all-cause mortality, acute myocardial infarction, or revascularization due to refractory angina (hazard ratio [HR]: 1.00; 95% confidence interval [CI]: 0.80 to 1.27).


Read also: Though Systolic BP Seems More Important, Diastolic BP Should Not Be Disregarded.


Historically, we assumed that the presence of ischemia signaled a higher-risk population and, thus, warranted an indication for revascularization (of any type) so as to protect the myocardium from the chronic effects of ischemia. However, this study does not support such assumption.

In conclusion, these results seem to be provisional and keep us on our toes until the long-term progress of the ISCHEMIA trial is published.

Original title: Association between stress testing–induced myocardial ischemia and clinical events in patients with multivessel coronary artery disease.

Reference: Larrosa Garzillo C et al. JAMA Intern Med.2019; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...